Novo Nordisk has announced positive topline results from Pioneer Teens, a phase 3a trial evaluating oral semaglutide for type 2 diabetes in children and adolescents aged 10–17 years.
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.
